Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMS8I1E)

Drug Name

2,4,4-triphenylimidazoline Drug Info

Synonyms

2,4,4-triphenylimidazoline; CHEMBL493970; SCHEMBL4463957; BDBM50257786

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Discontinued Drug(s)

Preclinical Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Neuropeptide Y receptor type 5 (NPY5R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CGP71683A	DMRYC08	Obesity	5B81	Discontinued in Phase 3	[2]
Velneperit	DMROSHN	Obesity	5B81	Discontinued in Phase 2	[3]
S-234462	DM80P4U	Obesity	5B81	Discontinued in Phase 1	[3]
Axovan-3	DM1JN6A	Eating disorder	6B82	Discontinued in Phase 1	[4]
FR-79620	DMXR287	Diabetic complication	5A2Y	Preclinical	[5]
GW-594884A	DMHUD27	Obesity	5B81	Preclinical	[5]
NPY5RA-972	DMXUCSN	Obesity	5B81	Preclinical	[5]
RWJ-49815	DMUGZMO	Fungal infection	1F29-1F2F	Terminated	[4]
AR-129330	DMUSYKG	Discovery agent	N.A.	Investigative	[6]
Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]	DMKANOH	Discovery agent	N.A.	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neuropeptide Y receptor type 5 (NPY5R)	TTY6EWA	NPY5R_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Discovery of substituted 2,4,4-triarylimidazoline derivatives as potent and selective neuropeptide Y Y5 receptor antagonists. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1670-4.
2	Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors. Neuropharmacology. 2007 May;52(6):1396-402.
3	Clinical pipeline report, company report or official report of Shionogi (2011).
4	Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
5	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
6	Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6.
7	Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]: a neuropeptide Y (NPY) Y(5) receptor selective agonist with a latent stimulatory effect on food intake in rats. Peptides. 2002 Aug;23(8):1485-90.